# Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

> **NCT01353703** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 224 (actual)

## Conditions studied

- Poliomyelitis
- Tetanus
- Acellular Pertussis
- Haemophilus Influenzae Type b
- Diphtheria
- Hepatitis B
- Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

## Interventions

- **BIOLOGICAL:** Infanrix hexa™

## Key facts

- **NCT ID:** NCT01353703
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-16
- **Primary completion:** 2013-02-25
- **Final completion:** 2013-02-25
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353703, "Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01353703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*